Cellex q Rapid Test receives FDA (Emergency Use Authorisation)

doctor longer 2.jpg

Why Choose Cellex Covid-19 Antibody q Rapid Test

  • GMP Manufacturing ISO 13485 certified, in compliance with US FDA’s QSR.

  • The test principle is developed by Cellex Inc. US a well-respected diagnostics and biopharmaceutical company since 2002.

  • Accurate (sensitivity/specificity: 93.75%/96.4%) COVID-19 results in 15 minutes.
    (
    Analytical test report)

  • IgG and IgM antibody test, indication of recent or past infection.

  • Completed third parties independent serology survey of prevalence studies in US.

  • For health care providers & professional use only.

AUTHORISED FOR EUA

MedPath

ISO 13485

coronavirus blue background.jpg

Cellex Antibody test has a high specificity to determine if a patient has had the virus and if they have developed antibodies to fight the virus.


A simple blood sample from patients can aid in identifying their immune response to SARS-CoV-2 indicating a recent or past infection.


The Cellex qSARS-CoV-2 IgG/IgM Cassette Rapid Test use the working test principle of Lateral flow immunoassay (LFIA) based on a sandwich method intended for the qualitative detection and differentiation of IgM and IgG antibodies which target the Nucleocapsid protein (N) and Spike Glyprotein (S) of SARS-CoV-2 in venipuncture whole blood, serum, or plasma (EDTA, citrate) specimens from patients.

Cellex q Rapid Test

Right Test @ Right Time

  • Affordable for different health care systems: Test can be used anywhere, no specialized training is required

  • Accurate and reliable results, robust performance.

  • Fast results allow physicians to make immediate immune response evaluation.

ANTIBODY TEST RESULT IN 15 MINUTES

CELLEX Covid-19 Antibody q Rapid test

A serology test (antibody test) such as Cellex Rapid q Rapid test is designed to help detect antibodies generated as part of the body’s immune response to fight the virus, SARS-CoV-2 coronavirus. It can deliver IgM and IgG Antibody test results in 15 minutes.


1 - The G Line and C Line are developed. This result is IgG positive or reactive, that indicates the presence of IgG anti- SARS-CoV-2

      virus, consistent with a recent or previous infection. **


2 - The M Line and C Line are developed. This result is IgM positive or reactive, that indicates the presence of IgM anti- SARS-CoV-2 

     virus, consistent with an acute or recent SARS-CoV-2 virus infection.**


3 - All of G, M and C Lines are developed. This result is IgG and IgM positive or reactive, that indicates the presence of IgG and IgM

     anti- SARS-CoV-2 virus, suggesting current or recent SARS-CoV-2 virus infection. **


4 - The C band is present, the absence of any burgundy colour in the both test bands (G and M) indicates that no anti-SARS-CoV-2

     virus antibodies are detected. The result is negative or non-reactive. **

1. IgG positive             2. IgM positive              3. IgG IgM Positive            4. IgG IgM Negative

* Invalid test

If the C Line does not develop, the assay is invalid regardless of colour development of the G or M Lines as indicated below. Repeat the assay with a new device.

** Test results interpretation :

 

  • The results obtained with this test should only be interpreted in conjunction with other diagnostic procedures and clinical findings.

  • Negative results do not prelude SAR-CoV-2 infection and should not be used as the sole basis for treatment or other patient management decisions.

  • Information regarding the immune response to SARS-CoV-2 is limited and still evolving. It is intended to be used as a screening test and aid in the diagnosis of SARS-CoV-2 viral infections. (indicating a recent or past infection).

  • For optimal test performance, proper sample collection is critical. Failure to follow the procedure may give inaccurate results . (Refer : WHO Guidelines on Drawing Blood: Best Practices in Phlebotomy. World Health Organization. 2010)

Ask your Doctor about Cellex Antibody Test results

Functions of Proteins

Spike glyprotein (S)

  • Critical for binding of host cell receptors to facilitate entry of host cell

Envelope small membrane protein (E)

  • Interacts with M to form viral envelope

 

Nucleoprotein (N)

  • Bound to RNA genome to make up nucleocapsid

Genomic RNA

 

  • Associated with a nucleoprotein within a capsid comprise of matrix protein

Membrane protein (M)

 

  • Central organiser of CoV assembly

  • Determines the shape of the viral envelope

The novel coronavirus detected in China in 2019 is closely related genetically to the SARS-CoV-1 virus. SARS emerged at the end of 2002 in China, and it caused more than 8 000 cases in 33 countries over a period of eight months. Around one in ten of the people who developed SARS died.


As of 24 April 2020, the COVID-19 outbreak had caused over 2 668 000 cases worldwide since the first case was reported in China in January 2020. Of these, more than 190 000 are known to have died.


As this is a new virus, no vaccine is currently available. Although work on a vaccine has already started by several research groups and pharmaceutical companies worldwide, it may be many months or even more than a year before a vaccine has been tested and is ready for use in humans.

@Britannica Inc.

SARS-CoV-2 Virus Structure

TIMELINE OF ANTIBODY DEVELOPMENT AND VIRUS INFECTION CYCLE

©2020 by Brands Direct International. 

All Rights Reserved.

Legal Statement

Privacy Policy

In collaboration with :

BRANDS DIRECT INTERNATIONAL SDN BHD (929163-V)

No 3 Jalan TP3 Tangkas Arena, 

Taman Perindustrian SIME UEP

47620 Subang Jaya

Selangor Darul Ehsan Malaysia

Toll Free Number : 1800 88 8089

Mobile & WhatsApp Number : +6017 205 3344

       +6017 659 8913

Email : sales@bdi.com.my

  • Facebook
  • Instagram
  • LinkedIn

HOME

COVID-19

WELLNESS

NEWS

CONTACT

ABOUT

Malaysia  |  Bangladesh  |  China  |  Vietnam  |  Indonesia